Latigo Biotherapeutics, Inc. (LTGO) Ownership - Who Owns Latigo Biotherapeutics, Inc.?
Latigo Biotherapeutics, Inc. (LTGO) Ownership Overview
- 28.68% Insiders
- 1.18% Mutual Funds
- 1.45% ETFs
- 68.68% Public Companies and Individual Investors
The ownership structure of Latigo Biotherapeutics, Inc. (LTGO) stock is a mix of institutional, retail, and individual investors. Approximately 2.63% of the company’s stock is owned by Institutional Investors, 28.68% is owned by Insiders, and 68.68% is owned by Public Companies and Individual Investors.
The ownership structure of Latigo Biotherapeutics, Inc. (LTGO) stock is a mix of institutional, retail, and individual investors. Approximately 2.63% of the company’s stock is owned by Institutional Investors, 28.68% is owned by Insiders, and 68.68% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Aug 09, 2026 | Foresite Capital Management V, Llc | $2,520,000 | |
| Aug 09, 2026 | James B. Tananbaum | $2,520,000 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 5am Ventures Vi, L.p. | 7,325,962 | Insider | 11.05% | 102,197,170 |
| Foresite Capital Management V, Llc | 3,414,544 | Insider | 5.15% | 47,632,889 |
| James B. Tananbaum | 3,414,544 | Insider | 5.15% | 47,632,889 |
| Westlake Biopartners Fund I, L.p. | 2,094,813 | Insider | 3.16% | 29,222,641 |
| Beth Seidenberg | 2,094,813 | Insider | 3.16% | 29,222,641 |
| Vanguard | 853,547 | Institution | 1.29% | 11,906,981 |
| Fidelity Select Portfolios | 692,816 | Institution | 1.04% | 9,664,783 |
| Sanofi | 672,788 | Insider | 1.01% | 9,385,393 |
| Schwab | 110,667 | Institution | 0.17% | 1,543,805 |
| Fidelity Rutland Square Trust Ii | 78,500 | Institution | 0.12% | 1,095,075 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Fidelity Select Portfolios | 692,816 | Institution | 1.04% | 9,664,783 |
| Fidelity Rutland Square Trust Ii | 78,500 | Institution | 0.12% | 1,095,075 |
| Vanguard Scottsdale Funds | 9,108 | Institution | 0.01% | 127,057 |
Top ETF Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard | 629,123 | Institution | 0.95% | 10,506,354 |
| Vanguard | 215,316 | Institution | 0.32% | 3,595,777 |
| Schwab | 98,674 | Institution | 0.15% | 1,533,394 |
| Schwab | 11,993 | Institution | 0.02% | 186,371 |
| Vanguard | 7,915 | Institution | 0.01% | 132,181 |
| Vanguard | 790 | Institution | <0.01% | 13,193 |
| Vanguard | 284 | Institution | <0.01% | 4,743 |
| Vanguard | 119 | Institution | <0.01% | 1,987 |
FAQ
What percentage of Latigo Biotherapeutics, Inc. (LTGO) stock is held by retail investors?
According to the latest TipRanks data, approximately 68.68% of Latigo Biotherapeutics, Inc. (LTGO) stock is held by retail investors.
Who owns the most shares of Latigo Biotherapeutics, Inc. (LTGO)?
5AM Ventures VI, L.P. owns the most shares of Latigo Biotherapeutics, Inc. (LTGO).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.